The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Antibody blockade of semaphorin 4D to sensitize pancreatic cancer to immune checkpoint blockade.
 
Luis I. Ruffolo
No Relationships to Disclose
 
Nicholas A. Ullman
No Relationships to Disclose
 
Benjamin Dale
No Relationships to Disclose
 
Katherine M. Jackson
No Relationships to Disclose
 
Paul Burchard
No Relationships to Disclose
 
Mary Georger
No Relationships to Disclose
 
Rachel Jewell
No Relationships to Disclose
 
Brian A. Belt
No Relationships to Disclose
 
Eva Galka
No Relationships to Disclose
 
Luke O. Schoeniger
No Relationships to Disclose
 
Crystal L. Mallow
Employment - Vaccinex
 
Elizabeth E. Evans
Employment - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - Inventor on following patents: Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent. U.S. Provisional Patent Application No. 62/473,731 Use of Semaphorin-4D inhibitory molecules in combination with an im (Inst)
 
Terrence Lee Fisher
Employment - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - Patent author, Vaccinex, Inc.
 
Maurice Zauderer
Employment - Vaccinex
Leadership - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - inventor on several patents assigned to Vaccinex, Inc. No royalty or other direct financial interest in patent.
 
David Linehan
Research Funding - MiNA Therapeutics (Inst)